As such, the correction of abnormal elevations in plasma prolactin, where it exists in metabolic syndrome patients, and the reestablishment of its normal circadian variation, is a metabolic benefit of circadian bromocriptine therapy [135,138,140]. The gene discussed is PRL; the disease is metabolic syndrome.